Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an inactivated whole-virion vaccine developed by Beijing Zhifei Lvzhu Biopharmaceutical, a subsidiary of Chongqing Zhifei Biological Products, for the prevention of hand, foot, and mouth disease (HFMD) caused by Enterovirus A71 (EV-A71). The vaccine is produced by propagating EV-A71 in Vero cell cultures and then inactivating the virus with formaldehyde. It is administered intramuscularly and is designed to stimulate the production of neutralizing antibodies against the EV-A71 virus, which is a major cause of severe HFMD and associated neurological complications in children. The vaccine has progressed through clinical trials, including Phase III studies, to evaluate its efficacy, safety, and immunogenicity in infants and young children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Enterovirus Type 71 Vaccine, Inactivated (Vero Cells).